Cite

HARVARD Citation

    Bracarda, S. et al. (2017). How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma. Expert review of anticancer therapy. 17 (3), pp. 227-233. [Online]. 
  
Back to record